| 货号 | ACFP302 |
| 别名 | BSC-1 cell growth inhibitor; cetermin; Glioblastoma-derived T-cell suppressor factor; G-TSF; MGC116892; polyergin; TGFB2; TGF-beta2; TGF-beta-2; transforming growth factor beta-2; transforming growth factor, beta 2 | 全称 | Transforming Growth Factor beta 2 |
| 反应种属 | Human |
| 来源 | Spodoptera frugiperda,Sf 9 (baculovirus)-derived Ala303-Ser414 Accession # P61812 Produced in an animal component free process (ACFP). |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 7042 (Human); 21808 (Mouse); 397084 (Porcine) |
| 内毒素水平 | <0.10 EU per 1 μg of the protein by the LAL method. |
| 生物活性 | Measured by its ability to inhibit the IL-4-dependent proliferation of HT‑2 mouse T cells. Tsang, M. et al. (1995) Cytokine 7:389. The ED50 for this effect is typically 0.025-0.25 ng/mL. |
| 溶解方法 | Reconstitute at 100 μg/mL in sterile 4 mM HCl |
| 背景 | TGF-beta 2 (transforming growth factor beta 2) is one of three closely related mammalian members of the large TGF-beta superfamily that share a characteristic cysteine knot structure (1 - 7). TGF-beta 1, -2 and -3 are highly pleiotropic cytokines proposed to act as cellular switches that regulate processes such as immune function, proliferation and epithelial-mesenchymal transition (1 - 4). Each TGF-beta isoform has some non-redundant functions; for TGF-beta 2, mice with targeted deletion show defects in development of cardiac, lung, craniofacial, limb, eye, ear and urogenital systems (2). Human TGF-beta 2 cDNA encodes a 414 amino acid (aa) precursor that contains a 19 aa signal peptide and a 395 aa proprotein (8). A furin-like convertase processes the proprotein to generate an N-terminal 232 aa latency-associated peptide (LAP) and a C-terminal 112 aa mature TGF- beta 2 (8, 9). Disulfide-linked homodimers of LAP and TGF-beta 2 remain non-covalently associated after secretion, forming the small latent TGF-beta 1 complex (8 - 10). Covalent linkage of LAP to one of three latent TGF-beta binding proteins (LTBPs) creates a large latent complex that may interact with the extracellular matrix (9, 10). TGF-beta is activated from latency by pathways that include actions of the protease plasmin, matrix metalloproteases, thrombospondin 1 and a subset of integrins (10). Mature human TGF-beta 2 shows 100% aa identity with porcine, canine, equine and bovine TGF-beta 2, and 97% aa identity with mouse and rat TGF-beta 2. It demonstrates cross-species activity (1). TGF-beta 2 signaling begins with binding to a complex of the accessory receptor betaglycan (also known as TGF-beta RIII) and a type II ser/thr kinase receptor termed TGF-beta RII. This receptor then phosphorylates and activates another ser/thr kinase receptor, TGF-beta RI (also called activin receptor-like kinase (ALK) -5), or alternatively, ALK-1. The whole complex phosphorylates and activates Smad proteins that regulate transcription (3, 11, 12). Use of other signaling pathways that are Smad-independent allows for disparate actions observed in response to TGF-beta in different contexts (11). |
| Accession # | P61812 |
| 运输条件 | Blue Ice |
| N-terminal Sequence Analysis | Ala303 |
| 预期分子量 | 12.7 (monomer) kDa |
| SDS-PAGE | 9-11 kDa, reducing conditions |
| 存放说明 | -20℃ |
| 纯度 | >97%, by SDS-PAGE under reducing conditions and visualized by silver stain |
| 参考文献 |
|
Recombinant Human Animal Component Free (ACFP) TGF‑ beta 2 inhibits IL-4-induced proliferation of HT‑2 mouse T cells. The ED50 for this effect is typically 0.025-0.25 ng/mL. | |
1 μg/lane of Recombinant HumanTGF-beta 2 (Catalog # ACFP302) was resolved with SDS-PAGE under reducing (R) andnon-reducing (NR) conditions and visualized by silver staining, showing bandsat 12.1 and 23.4 kDa, respectively. |
